Plain-English translation of NCT07096128 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 clinical trial testing a new treatment called [177Lu] Lu-PSMA-XT for men with metastatic prostate cancer—prostate cancer that has spread beyond the prostate to other parts of the body. The medication works by delivering targeted radiation directly to cancer cells that express a specific marker called PSMA. Researchers want to understand how safe this treatment is, how well it works, and what dose is best for patients.
Men with advanced prostate cancer often run out of effective treatment options after trying standard therapies like hormone treatments and chemotherapy. This medication represents a new approach—using targeted radiation to kill cancer cells while sparing healthy tissue—and may help patients whose cancer no longer responds to conventional treatments.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive injections of the new medication at a hospital or clinic. The study team would monitor your safety closely through blood tests, imaging scans, and physical exams to measure how your body tolerates the treatment and whether your cancer responds. The exact schedule of visits and treatments will be explained to you by the research team, and you will be asked to return for follow-up visits to check on your progress.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China